Therefore, CD47 has also become a new target for HR-MDS, and anti-CD47 monoclonal antibodies such as Magrolimab, TTI-621 and CC-90002 were finally introduced into the treatment. The gene discussed is CD47; the disease is myelodysplastic syndrome.